Raspberry Pi Holdings plc designs and develops single-board computers, compute module, and semiconductors in the United Kingdom, Europe, the United States, Asia Pacific, and internationally. The company provides computers and microcontrollers, cameras and displays, add-on boards, power supplies and cables, cases, and peripherals. It offers Raspberry Pi Connect, a secure remote access solution for Raspberry Pi OS which allows to connect to your Raspberry Pi desktop from any browser; Raspberry Pi Desktop for any PC or Apple Mac computer; Raspberry Pi Imager, which installs Raspberry Pi OS and other operating systems to a microSD card and OS software products; and Raspberry Pi OS, a supported operating system for organizations. In addition, the company offers Raspberry Pi Press, which produces magazines and books, as well as the Raspberry Pi Store. The company serves resellers and original equipment manufacturers; industrial and embedded applications; enthusiasts; and educators. The company was founded in 2012 and is headquartered in Cambridge, the United Kingdom.
Research context
NGM Biopharmaceuticals, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Technology
- Industry
- Electronic Components
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
NGM Biopharmaceuticals, Inc is currently in a long term downtrend where the price is trading 10.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.4.
NGM Biopharmaceuticals, Inc's total revenue sank by 36.4% to $20M since the same quarter in the previous year.
Its net income has dropped by 75.6% to $-28M since the same quarter in the previous year.
Finally, its free cash flow fell by 29.7% to $-20M since the same quarter in the previous year.
Based on the above factors, NGM Biopharmaceuticals, Inc gets an overall score of 1/5.